Skip to main content
Seestargardt logo.

Beyond diagnosis: Implementing active management strategies in Stargardt disease

Proactive management and care team collaboration are critical to protecting remaining visual function. Comprehensive patient support, including access to advocacy groups and assistive devices, can further empower patients to navigate daily life with Stargardt disease type 1 (STGD1).1-4

Collaborate with other care providers to manage the confirmed patient

Effective collaboration and open communication across the care team are highly valuable when managing Stargardt disease, especially as the disease progresses and the patient’s needs evolve over time.1 Fostering a continuous communication loop is important for accurately tracking Stargardt disease progression and impact, and providing timely access to essential patient resources, including lifestyle, occupational, and psychosocial support.1,4

Advocacy groups offer education and support to help patients understand Stargardt disease2-4

Encourage your patients to connect with established advocacy groups like Foundation Fighting Blindness or Prevent Blindness. These organizations offer useful, easy-to-understand educational materials, support options, and peer connection.

Foundation Fighting Blindness My Retina Tracker logo.

For patients interested in contributing to research or staying informed about clinical trials, registering with My Retina Tracker can be a valuable step to connect them with active studies and researchers.

Supporting a patient’s daily independence is vital2-4

Facilitate access to practical low-vision solutions, including:

Magnifiers
Screen readers
Other adaptive
technology aids

Addressing psychosocial needs

Beyond the physical impacts of Stargardt disease, this condition can also have significant psychosocial impacts on patients.4,5

Patients often experience a range of emotions, including frustration, worry, and sadness.5 Many also face social difficulties, such as trouble with facial recognition or discussing their condition, which can lead to social withdrawal.4,5

Acknowledging the emotional toll of Stargardt disease is critical

Prioritize mental health4:

  • Recommend that patients consider talking with a mental health professional4
  • Get patients connected with patient communities and advocacy groups for emotional support and practical advice4

Adaptations for daily living5:

  • Suggest patients consult low-vision service organizations on adapting the home environment for better safety and lighting5
  • Encourage them to advocate for educational and workplace accommodations, like specialized software or preferred seating5
While patients with Stargardt disease can overcome its challenges, almost half find it hard to discuss their condition, leading to social withdrawal and strained relationships4,5

Looking toward the future of Stargardt disease care

An active therapeutic pipeline including small molecule, gene, and stem cell therapies is currently being researched, signaling a profound shift in the landscape for Stargardt disease. These emerging possibilities underscore the critical importance of early diagnosis and proactive patient management today.6,7

Your continued involvement as part of the Stargardt care team is crucial, whether providing direct management or through timely referrals and comanagement. Your collaborative efforts in diagnosis, monitoring, and support are instrumental in empowering patients and preparing them for a future rich with new therapeutic possibilities for preserving their vision.1,2,4,7

Visit patient & caregiver site
Get another perspective
References:
  1. Caltrider D, Gupta A, Tripathy K. Evaluation of visual acuity. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2026. Updated May 1, 2024. Accessed August 28, 2026. https://www.ncbi.nlm.nih.gov/books/NBK564307/
  2. Ghenciu LA, Hațegan OA, Stoicescu ER, Iacob R, Șışu AM. Emerging therapeutic approaches and genetic insights in Stargardt disease: a comprehensive review. Int J Mol Sci. 2024;25(16):8859. doi:10.3390/ijms25168859
  3. Vandersmissen I, Geers J, Denee T, et al. The socioeconomic impact of inherited retinal dystrophies (IRDs) in Belgium: a cost-of-illness study. PLoS One. 2026;21(1):e0339332. doi:10.1371/journal.pone.0339332
  4. Abu Serhan H, Ahmed A, Sbei O, et al. Mental health outcomes in patients with inherited retinal diseases: a systematic review and meta-analysis. Int J Retina Vitreous. 2026;12:45. doi:10.1186/s40942-026-00820-7
  5. Roborel de Climens A, Tugaut B, Barbosa CD, Buggage R, Brun-Strang C. Living with Stargardt disease: insights from patients and their parents. Ophthalmic Genet. 2021;42(2):150-160. doi:10.1080/13816810.2020.1855663
  6. Estrada-Puente C, Morales PC, Maldonado RS. Novel therapies for Stargardt disease. Retin Physician. 2025;22(October):19-22.
  7. Li AS, Morales PC, Estrada-Puente C, Maldonado RS. Factors influencing the delayed diagnosis of Stargardt disease and Impact on therapeutic opportunities. Retina. 2026;46(2):367-372. doi:10.1097/IAE.0000000000004691